In tablet manufacturing for equine and companion animal use, oxyphenbutazone is processed by wet granulation rather than direct compression because the API exhibits cohesive flow and the finished oral solid form typically requires a low unit dose with tight content uniformity. Pre-blending of the active substance with lactose monohydrate, maize starch, and microcrystalline cellulose is followed by binder incorporation using an aqueous or hydroalcoholic povidone K30 solution in a high-shear granulator. The wet mass is passed through a 1.0 mm sieve and dried in fluid-bed equipment until loss on drying under USP <731> falls below 2.0% w/w; residual moisture above this threshold is associated with picking and sticking on rotary tablet presses during extended production campaigns. Compression is performed on a 21-station rotary press with compression force adjusted to produce friability below 0.8% under USP <1216>, while disintegration is confirmed per USP <701>. For film-coated tablets, a non-functional aqueous film coating may be applied to mask bitterness; a pH-dependent enteric coating is not applied unless the target species and dosing regimen require delayed release to the distal small intestine. Batch-record limits commonly specify magnesium stearate addition at 0.25% to 0.5% w/w and total lubricant mixing below 120 seconds because over-lubrication can reduce tablet tensile strength and slow dissolution in 0.1 M hydrochloric acid. Dissolution acceptance criteria for immediate-release veterinary tablets are established product-specifically; compendial testing uses USP <711> Apparatus 2 with 900 mL of 0.1 M hydrochloric acid or pH 6.8 phosphate buffer at 50 rpm in regulatory filings. Content uniformity is controlled under USP <905>; acceptance values above 15.0 trigger batch rejection. Stability batches are stored under ICH Q1A(R2) conditions, and photostability testing under ICH Q1B is required because oxyphenbutazone degrades under artificial daylight in aqueous and solid matrices. The free-acid form exhibits slower dissolution in neutral media than in acidic media, while more soluble salt forms may require added desiccant protection to prevent moisture uptake during storage.

Which Particle-Size Parameters Govern Resuspendability and Syringeability in a Sterile Injection?

Sterile injectable suspensions of oxyphenbutazone intended for intramuscular administration in horses are constructed as aqueous suspensions because the free acid has limited aqueous solubility and cannot be formulated as a true solution at the concentrations required for practical dose volumes. The API is reduced to micronized dimensions using a fluid-energy mill equipped with an air classifier, and particle-size distribution is measured by laser diffraction under USP <429>. Release specifications are product-specific, but a d90 below 20 µm is commonly applied to maintain passage through 21G needles under veterinary field conditions. Overmilling to submicron ranges may increase dissolution but also increases surface free energy, which can exacerbate crystal growth, sedimentation, and caking during storage. Suspension vehicles typically contain polysorbate 80, sodium carboxymethylcellulose, and a preservative system; benzyl alcohol is omitted from feline injectable presentations due to documented species-specific adverse reactions, while multi-dose equine presentations may include it only after safety assessment. Sterility testing is conducted per USP <71>, bacterial endotoxin limits are controlled per USP <85>, and particulate matter is assessed by USP <788>. Terminal steam sterilization at 121°C for 15 minutes cannot be uniformly applied to oxyphenbutazone suspensions because the suspending agent may lose viscosity and the API may undergo crystal transformation or polymorphic conversion. Aseptic manufacturing is therefore typical: vehicle components are heat-sterilized, while the micronized API is sterilized by gamma irradiation or validated ethylene oxide treatment. Syringeability is checked with a texture analyzer or syringe force tester using a specified needle gauge and withdrawal speed; resuspendability is assessed by repeated manual inversion cycles followed by assay of the upper, middle, and lower vessel zones. Published stability data for oxyphenbutazone in multi-dose parenteral vehicles at fixed pH gradients are limited; manufacturer-specific thermal stress studies are required before terminal sterilization is selected.

Hard gelatin capsule filling of oxyphenbutazone at single-dose strengths below 100 mg requires particular attention to blend segregation and flow into the dosing disc. Because the API is cohesive, dry granulation or wet granulation is generally performed before encapsulation rather than filling raw powder blends; roller compaction followed by milling produces granules with a tapped bulk density by USP <616> within a product-specific range that balances flowability and content uniformity. Capsule machines with tamping pins exert low compression, so granule flow index and Carr index are monitored as in-process indicators. Magnesium stearate is added at 0.25% to 0.5% w/w and blended for a fixed time below 5 minutes to prevent hydrophobic film formation on granule surfaces. In-process verification samples are collected at the start, middle, and end of encapsulation, and content uniformity is controlled by USP <905>. Dissolution from hard gelatin capsules may be slower than from tablets if shell crosslinking occurs under trace formaldehyde exposure; dissolution testing per USP <711> with the addition of gastric enzyme is required where shell crosslinking is suspected. Empty capsule shells are stored below 45% relative humidity to prevent brittle fracture on high-speed filling equipment.

Oral Powder Reconstitution in Drinking Water Requires pH Control and Light Protection

Water-soluble oral powders containing oxyphenbutazone as a freely soluble salt are intended for administration in drinking water to horses or other non-food species. The free acid has poor aqueous solubility, so the formulation relies on pH adjustment with sodium carbonate or sodium bicarbonate and may contain polyethylene glycol 400 as a dispersing agent when packaged as a soluble powder. Reconstituted solutions are vulnerable to photodegradation; pilot stability studies under ICH Q1B show loss of assay when clear plastic troughs are exposed to direct sunlight, so the commercial pack should be foil-lined and dosing instructions should specify shaded, non-metal water containers. Chemical stability in drinking water is pH-dependent; an acidic pH below 6.0 may precipitate the free acid and reduce dosing accuracy, while alkaline conditions above 9.0 may accelerate oxidative degradation of the phenylbutazone-derived chromophore. Blending homogeneity of the dry powder is verified by sampling across the blender with a thief probe; acceptance criteria commonly require assay relative standard deviation not more than 5.0% and moisture below 2.0% by USP <731> before filling into foil sachets. Use in food-producing animals is prohibited where residues in meat or milk are regulated; the label must specify the non-food species restriction and withdrawal period is therefore not applicable.

Top-spray fluid-bed granulation of oxyphenbutazone oral granules produces porous agglomerates with improved wettability compared with wet-massed material. Granulation liquid containing povidone and polysorbate 80 is sprayed onto a fluidized bed of API, lactose, and microcrystalline cellulose; inlet air temperature is maintained between 45°C and 55°C to avoid thermal degradation while achieving granule moisture below 2.0%. The resulting granules are classified through a 0.8 mm and 1.4 mm sieve stack; oversized material is milled and re-processed. Friability is measured by tumbling a 10 g sample in a 250 mL glass jar containing glass beads for 15 minutes; acceptance requires less than 1.0% fines. Bulk density by USP <616> is controlled within specified release limits to ensure consistent dosing cup or sachet fill. Dissolution of granular formulations is tested in 900 mL of pH 6.8 phosphate buffer at 50 rpm using USP <711> Apparatus 2; the granular matrix should release not less than 75% Q within 45 minutes, but this limit is product-specific and must be justified by species-specific pharmacokinetic data. Granule presentations are particularly subject to dose-splitting errors in field conditions, so dosing instructions should be supported by weight-based cup calibrations rather than volumetric approximations alone.

Premix Segregation and Carryover Control in Non-Food Equine Feed Mills

Oxyphenbutazone premixes for non-food equine use are manufactured at low API concentration on carriers such as calcium carbonate, rice hulls, or wheat middlings. The primary process risk is segregation: oxyphenbutazone granulate has a higher bulk density than fibrous carriers, leading to settling during silo discharge and truck transport. Mill validation therefore includes sampling at multiple points in a ribbon mixer or paddle mixer at 1, 3, and 5 minutes to determine assay coefficient of variation; acceptance criteria in several regulatory frameworks require CV not more than 5.0% for medicated premix homogeneity. Cleaning validation after oxyphenbutazone batches is conducted under 21 CFR 211.67 and 21 CFR 211.110; carryover into food-producing animal feed is prohibited where oxyphenbutazone residues are not permitted. Analytical detection in feed by HPLC with UV detection at 254 nm is used; limit of quantification must fall below the cross-contamination threshold derived from the equine dose minus a conservative carryover factor. Published data for specific oxyphenbutazone premix segregation thresholds is limited; site-specific recovery studies are required to establish flush sequences and discards on shared production trains. Premix packs are specified with desiccant when the carrier is hygroscopic and are labeled with maximum incorporation rate, target animal safety statement, and a prohibition against redirection to food-animal channels.

When Terminal Sterilization Shifts Buffered Solution pH Outside the Stable Range

Aqueous injectable solutions of oxyphenbutazone are achievable only when the API is presented as a soluble salt or when co-solvents and pH modifiers are included. A formulation platform commonly contains propylene glycol or polyethylene glycol 400 with water for injection; the free acid is dissolved after addition of sodium hydroxide or meglumine until a target pH of 7.4 to 8.0. Terminal sterilization by autoclave at 121°C for 15 minutes must be supported by sterility assurance and stability data; thermal exposure can shift pH due to hydrolysis of co-solvent esters and can produce visible discoloration from oxidative degradation of the phenylbutazone-derived chromophore. For this reason, terminal cycle design is based on bioburden and D-value studies rather than a fixed generic cycle. Sterility testing follows USP <71>, bacterial endotoxin limits follow USP <85>, and package integrity of amber Type I glass ampoules or vials after terminal sterilization is verified by vacuum dye ingress under USP <1207>. Multi-dose preparations require preservative efficacy testing per USP <51>; preservative selection must avoid incompatibility with the buffering system and with oxyphenbutazone co-solvents. Nylon membrane filters may adsorb phenylbutazone-class molecules, so filter validation is required because API loss can exceed 5% with certain membrane types. Aqueous solution presentations are the most degradation-prone of the oxyphenbutazone dosage forms considered, and each commercial batch is placed on stability monitoring under ICH Q1A(R2) with assay, related substances, pH, particulate matter, and sterility intervals matched to finished product storage conditions.